Bionano Genomics, Inc. — 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; comparative figures are for 2018. The filing was signed March 10, 2020. Bionano sells the Saphyr genome-analysis platform, consumables and related services, primarily for research use; customers may use the system to develop laboratory-developed tests.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Total revenue | $10.1 million | $12.0 million |
| Gross profit / gross margin | $3.4 million / 33.2% | $3.3 million / 27.4% |
| Operating expenses | $29.2 million | $23.7 million |
| Operating loss | $25.9 million | $20.4 million |
| Net loss | $29.8 million | $18.5 million |
| Cash used in operating activities | $29.5 million | $19.9 million |
| Cash and cash equivalents at year-end | $17.3 million | $16.5 million |
| Debt carrying value at year-end | $20.1 million, classified current | $9.0 million, of which $9.0 million was long-term |
Product revenue fell 17% to $9.5 million: instrument revenue declined 20% to $6.8 million and consumables revenue declined 10% to $2.7 million. Service and other revenue rose 22% to $0.7 million. Gross margin improved as cost of revenue fell faster than revenue, but operating expenses rose 23%, principally due to expanded sales, marketing and administrative staffing and public-company costs. Interest expense increased 66% to $2.3 million; a $1.3 million debt-extinguishment loss also weighed on results. The 2018 results included a $4.0 million gain from warrant fair-value changes, which did not recur.
At year-end, current assets were $28.3 million and current liabilities were $26.4 million. The company reported an accumulated deficit of $102.6 million and stockholders’ equity of $3.6 million. Management said existing cash was expected to fund operations and obligations only through the second quarter of 2020.
Changes, outlook and material matters
- Quarterly comparison: Fourth-quarter 2019 revenue was $2.8 million versus $4.0 million in Q4 2018; net loss was $7.9 million versus $6.4 million.
- Financing and dilution: The October 2019 offering generated approximately $18.0 million gross proceeds and included common shares, pre-funded warrants and warrants. The company also raised funds through debt and stock sales. Common shares outstanding increased to 34.3 million at year-end from 10.1 million a year earlier; 37.8 million were outstanding as of March 6, 2020.
- Debt covenant breach and amendment: The company failed certain Innovatus financial covenants at September 30 and December 31, 2019. A March 2020 amendment waived the December breach but required a $2.1 million principal prepayment, paid on March 6, and another $2.9 million payment by the earlier of April 30, 2020 or a qualifying equity financing. It also required a $200,000 waiver fee and a $100,000 prepayment fee. The debt is secured by substantially all assets, including intellectual property.
- Going concern: The auditor issued an unqualified opinion on the financial statements but included an explanatory paragraph citing substantial doubt about the company’s ability to continue as a going concern. Continued operations depend on additional financing, revenue and compliance with debt terms.
- Business outlook: The filing provides no formal revenue or earnings guidance. Management expected continued losses and investment in commercialization and R&D. It projected sample costs below $300 in 2020 and below $100 in 2021, and throughput of 9–12 human samples per day by the end of 2020; these are company expectations, not reported outcomes.
- Commercial and regulatory risks: Saphyr is labeled for research use only, while clinical use may trigger FDA or other regulatory requirements. Adoption depends partly on customer validation studies, reimbursement prospects and development of LDTs. The company cited long sales cycles, competition, reliance on single or limited-source manufacturers and reagent suppliers, and uncertainty about market acceptance.
- COVID-19 exposure: The filing warned that the emerging outbreak could disrupt sales, travel, distribution and suppliers, particularly in Asia-Pacific, which represented 14% of 2019 revenue; China represented 5%.
- Internal controls: Management identified a material weakness related to insufficient financial-reporting resources and segregation of duties; disclosure controls were not effective at year-end. Remediation was underway but not complete as of March 10, 2020.
Important facts for investors to verify
- Available cash, subsequent financing and the actual cash runway relative to ongoing operating cash burn.
- Completion and funding of the required $2.9 million debt prepayment, payment of fees, and ongoing Innovatus covenant compliance.
- Share and warrant dilution, including the terms and exercise status of outstanding securities from the 2019 offering.
- Quarterly instrument placements, installed-base utilization and recurring consumables growth, given the annual revenue decline.
- Progress and results from clinical validation studies, regulatory developments affecting RUO products and LDTs, and reimbursement pathways.
- Whether the material weakness is remediated and whether future filings maintain reliable financial reporting.